French drug company Sanofi-Aventis (SNY) Thursday said it has completed the acquisition of 100% of Chattem, Inc. (CHTT), which is now a wholly-owned subsidiary of the Sanofi-Aventis Group. MAIN...
Chattem, Inc. (NASDAQ: CHTT) (“Chattem”) announced that it has commenced a tender offer (the “Tender Offer”) to repurchase all of its outstanding 2.00% convertible senior notes...
As previously reported on Chattem, Inc.'s (NASDAQ: CHTT) (the “Company”) Form 8-K filed on February 12, 2010 (the “Form 8-K”), the Company is no longer in compliance with NASDAQ...
Chattem, Inc. (NASDAQ: CHTT) announced that, pursuant to the terms of the indentures (the “Indentures”) governing its 2.00% convertible senior notes due 2013 and 1.625...
French drug company Sanofi-Aventis Tuesday said it has completed its tender offer for all outstanding shares of common stock of Chattem, Inc (CHTT). MAIN FACTS: - As of the expiration time...
PARIS, Feb. 9 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has successfully completed its tender offer for all outstanding shares of common...
NEW YORK, Feb. 2 /PRNewswire/ -- NTELOS Holdings Corp. (NASDAQ:NTLS) will replace Chattem Inc. (NASDAQ:CHTT) in the S&P SmallCap 600 index on a date to be announced. Chattem is being acquired...
Drug company Sanofi-Aventis (SNY) Friday expanded its reach in the consumer drugs market to China, with the creation of a vitamin and mineral supplements joint venture with Minsheng Pharmaceutical...
Drug company Sanofi-Aventis (SNY) Friday expanded its reach in the consumer drugs market to China, with the creation of a vitamin and mineral supplements joint venture with Minsheng Pharmaceutical...
Chattem, Inc. (NASDAQ: CHTT) announced that, pursuant to the terms of the indentures (the “Indentures”) governing its 2.00% convertible senior notes due 2013 and 1.625...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.